JAAD International (Sep 2024)

Immune stimulus exposure as a trigger for the development of chronic pruritus and circulating blood type 2 inflammationCapsule Summary

  • Jaya Manjunath, BS,
  • Viviane Liao, BS,
  • Anusha Kambala, BS,
  • Aaron Bao, BA,
  • Alexander L. Kollhoff, MD,
  • Emily Z. Ma, BS,
  • Brenda Umenita Imo, MS,
  • Hannah Cornman, BS,
  • Sriya V. Reddy, BS,
  • Kevin K. Lee, BS,
  • Weiying Lu, BS,
  • Selina M. Yossef, BA,
  • Madan M. Kwatra, PhD,
  • Shawn G. Kwatra, MD

Journal volume & issue
Vol. 16
pp. 97 – 102

Abstract

Read online

Background: Chronic pruritus (CP) is a poorly characterized condition associated with intense pruritus without a primary skin eruption. This condition tends to emerge more commonly in older adults, and there is limited research on triggering factors. Objective: To explore the clinical characteristics and pathophysiology of CP following exposure to an immune stimulus. Methods: Clinical characteristics and plasma samples were collected from 15 patients who developed CP following an immune stimulus such as checkpoint inhibitors or vaccination. A multiplex panel was used to analyze plasma cytokine concentrations within these patients. Results: Most immunotherapy-treated patients experienced CP during treatment or after 21 to 60 days of receiving treatment, while vaccine-stimulated patients developed pruritus within a week of vaccination. Plasma cytokine analysis revealed elevated levels of 12 cytokines in patients with immune-stimulated CP compared to healthy controls. Notably, T helper 2 (Th2) related cytokines interleukin (IL)-5 (fold change 2.65; q < 0.25) and thymic stromal lymphopoietin (fold change 1.61 q < 0.25) were upregulated. Limitations: Limitations of this study include limited sample size, particularly in the plasma cytokine assay. Conclusions and Relevance: This study reveals triggers of CP development and describes alterations in blood Th2 markers in patients with CP, including IgE, increased blood eosinophils, and cytokines IL-5 and thymic stromal lymphopoietin.

Keywords